

Prediction of clearance from the HepaRG cell system: comparison with human hepatocytes for a range of substrates

 Ugo Zanelli¹, Nicola Pasquale Caradonna¹, David Hallifax², James Brian Houston²
¹Met Profiling Unit, Screening & Technology Department, Siena Biotech, Strada del Patricio e Belguardo 35, 53100 Siena, Italy
²School of Pharmacy & Pharmaceutical Sciences, The University of Manchester, Manchester, UK

Introduction

Predictions of in vivo intrinsic clearance (CL_{int}) from cryopreserved human hepatocytes may vary considerably from donor to donor and pooling has been used to reduce this effect. HepaRG have been proposed as an alternative complete model to evaluate hepatotoxicity with potential as a quantitative model for prediction of metabolic clearance. The HepaRG cell line is derived from a liver tumor of a female patient suffering from hepatocarcinoma and after appropriate culture procedures differentiated in hepatocyte-like and biliary-like cells, in a ratio of 1:1 expressing a relevant set of drug metabolism enzymes, transporters and hepatobiliary markers (1). In this work, we compare the intrinsic clearance obtained for a set of 40 well known drugs using a donor pool of human cryopreserved hepatocytes with those obtained with the hepatoma-derived cell line HepaRG.

Materials & Methods

Differentiated cryopreserved HepaRG cells from Biopredic Int. and pooled human cryopreserved hepatocytes from CellDirect (250,000/ml) were used. Disappearance of the compounds (1 μ M) was followed up to 45min and CL_{int} derived by dividing the fitted constant K in eq.1 by the concentration of cells, using the hepatocellularity parameters reported (2,3) and estimating the non-specific binding eq. 2 (4):

$$\text{eq.1: } C_t = C_0 \cdot e^{-k_d \cdot t}$$

$$\text{eq.2: } f u_{heps} = \frac{1}{1 + 125 \cdot V_R \cdot 10^{0.072 \log \frac{P}{D} + 0.067 \log \frac{P}{D} - 1.126}}$$

CL_{int} was deduced by CL in vivo according to Well Stirred model (WS) eq.3 or Parallel Tube (PT) eq. 4 models:

$$\text{eq.3: } CL_{int} = \frac{CL_b}{\frac{f u_p}{K_b} \cdot \left(1 - \frac{CL_b}{Q_H}\right)}$$

$$\text{eq.4: } CL_{int} = -\ln \left[\frac{Q_H - CL_b}{Q_H} \right] \cdot \frac{Q_H}{f u_p / R_b}$$

The accuracy was measured by average fold error (AFE) eq. 5: $afe = 10^{\frac{1}{n} \sum \log \frac{\text{predicted}}{\text{observed}}}$

Results

CL_{int} measured from HepaRG cells closely correlated with CL_{int} measured with cryopreserved hepatocytes (Figure 1).

Prediction of Clearance with both Hepatocytes (Fig. 2A) and HepaRG (Fig. 2B) was very variable, similar to previous experience (5).

No significant amelioration was achieved using PT instead of WS




Fig.2B:

Comparison of CL_{int} predicted from HepaRG cells and CL_{int} in vivo




Fig. 2A:

Comparison of CL_{int} predicted from cryopreserved Human hepatocytes and CL_{int} in vivo

For both cryopreserved hepatocytes and HepaRG, on average, the cells underpredicted unbound CL_{int} derived from in vivo plasma clearance, with marginal differences in AFE being dependent on the liver model used: 1.9 and 1.4 for the well stirred (WS) and parallel tube (PT) respectively, in cryopreserved hepatocytes; and 2.7 and 1.8 for the WS and PT model respectively, in HepaRG.

In both systems, AFE was dependent on clearance, with increasing under-prediction observed with increasing clearance.

Clint in vivo (WS)	AFE			
	<10 ml/min/kg	10-100 ml/min/kg	100-1000 ml/min/kg	>1000 ml/min/kg
Cryopreserved Pooled Hepatocytes	0.4	1.4	2.7	8.5
HepaRG	1.6	1.4	2.8	7.2

Greater under-prediction was observed with increasing protein binding irrespective of liver model (Figure 3).




Fig.3:

fold errors as function of Protein binding. 3 folds limit are shown

Limitations to in-vitro Clearance are not due to the permeability of compounds to hepatocytes, since apparent permeability, as assessed by PAMPA, did not correlate with the fold errors of Fig. 3 (data not shown). This suggests that the main difference between in vivo and in vitro in terms of permeability may be due to transporters activity.

Conclusion

A novel system for prediction of clearance, the HepaRG cell, has been shown for the first time to offer drug metabolising enzyme activity at the same level as pooled human hepatocytes which would enable quantitatively similar results.

Both the HepaRG and hepatocyte systems show clearance dependent prediction bias which appears to be related to protein binding.

Possible improvements to prediction methodology for hepatocytes, such as empirical correction of bias, could be equally applied to the HepaRG system.

References

1. Josee R, Aninat C, Glaise D, Dumont J, Fossard V, Morel F, Poul JM, Guguon- Gullouze C, Gullouze A. Long-term functional stability of human HepaRG hepatocytes and use for chronic toxicity and genotoxicity studies. *Drug Metab Dispos.* 2008; 36, 1111-1118.
2. Hakooz N, Ito K, Rowden H, Gill H, Lemmers L, Boobis AR, Edwards RJ, Carlile DJ, Lake BG and Houston JB (2006) Determination of a human hepatic microsomal scaling factor for predicting in vivo drug clearance. *Pharm Res* 23: 533-9.
3. Davies B and Morris T (1993) Physiological parameters in laboratory animals and humans. *Pharm Res* 10 (7): 1093-1095.
4. Kilford, P.; Gortz, M.; Houston, J.B. and Galatin, A. (2008). Hepatocellular binding of drugs: correction for unbound fraction incubations using microsomal binding or drug lipophilicity data. *Drug Metab. Dispos.*, 36: 1194-1197.
5. Hallifax D, Foster JA and Houston JB. (2010). Prediction of human metabolic clearance from in vitro systems: retrospective analysis and prospective view. *Pharm Res, Online First*, July 2010.